InvestorsHub Logo

ziploc_1

06/01/23 6:28 AM

#409917 RE: BobWayne #409916

Bob...QUOTE...“We are glad to receive this regulatory approval of VASCEPA from the NMPA China, and we are looking forward to securing reimbursement for this important product for patients and to a future CVRR indication approval,” said Rebecca Xu, Vice President of Clinical Development, EDDING."

THIS IS HUGE!...The next vital information we need is about reimbursement.

Amarin already up in pre-market!

Jasbg

06/01/23 7:01 AM

#409920 RE: BobWayne #409916

BW, Might have been what Sarissa / Denner has been waiting for (why the silence).

Lets hope its the beginning of the turnaround :)

rosemountbomber

06/01/23 7:13 AM

#409923 RE: BobWayne #409916

Thanks Bob. This sounds like strictly the Marine indication. Were we expecting R-I indication?

Invest83838

06/01/23 8:09 AM

#409933 RE: BobWayne #409916

China approval normally would have made the stock price increase significantly

but this is, of course, Amarin

and we "might" get and stay above 1.25 today lol

Well, hopefully Denner & crew will eventually fully capitalize on this opportunity